Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions

SIMPLE SUMMARY: The advent of immune checkpoint inhibitors has dramatically changed the history of advanced renal cell carcinoma treatment. Their use in first-line therapy provides an undeniable advantage in terms of survival; nevertheless, a considerable proportion of patients undergo disease progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sammarco, Enrico, Manfredi, Fiorella, Nuzzo, Amedeo, Ferrari, Marco, Bonato, Adele, Salfi, Alessia, Serafin, Debora, Zatteri, Luca, Antonuzzo, Andrea, Galli, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296725/
https://www.ncbi.nlm.nih.gov/pubmed/37370782
http://dx.doi.org/10.3390/cancers15123172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296725/
https://www.ncbi.nlm.nih.gov/pubmed/37370782
http://dx.doi.org/10.3390/cancers15123172

Ejemplares similares